MX2016007604A - Analogos de heteroaril indol biciclico utiles como moduladores de ror. - Google Patents

Analogos de heteroaril indol biciclico utiles como moduladores de ror.

Info

Publication number
MX2016007604A
MX2016007604A MX2016007604A MX2016007604A MX2016007604A MX 2016007604 A MX2016007604 A MX 2016007604A MX 2016007604 A MX2016007604 A MX 2016007604A MX 2016007604 A MX2016007604 A MX 2016007604A MX 2016007604 A MX2016007604 A MX 2016007604A
Authority
MX
Mexico
Prior art keywords
bicyclic heteroaryl
rorßt
ror gamma
gamma modulators
analogues useful
Prior art date
Application number
MX2016007604A
Other languages
English (en)
Inventor
Das Sanjib
Sundarlal Chaudhari Sachin
Thomas Abraham
Ramesh Pardeshi Shailesh
Govindrao Deshmukh Vishal
Dilip Wadekar Prashant
Khairatkar-Joshi Neelima
Manish Shah Daisy
Bajpai Malini
Original Assignee
Glenmark Pharmaceuticals Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glenmark Pharmaceuticals Sa filed Critical Glenmark Pharmaceuticals Sa
Publication of MX2016007604A publication Critical patent/MX2016007604A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/12—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Indole Compounds (AREA)

Abstract

La presente invención se refiere a compuestos de fórmula (I) y sales farmacéuticamente aceptables de los mismos, en la cual X, X1, M, R2, R3, R4, R5, m, n, y p son como se definen en la presente, los cuales son activos como moduladores del receptor gamma t huérfano (ROR?t) relacionado con retinoides. Estos compuestos previenen, inhibir, o suprimen la acción de ROR?t y por lo tanto son útiles en el tratamiento de enfermedades, trastornos, síndromes o afecciones mediados por ROR?t tales como, por ejemplo, dolor, inflamación, COPD, asma, artritis reumatoide, colitis, esclerosis múltiple, enfermedades neurodegenerativas y cáncer. (ver Fórmula).
MX2016007604A 2013-12-10 2014-12-09 Analogos de heteroaril indol biciclico utiles como moduladores de ror. MX2016007604A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
IN3853MU2013 2013-12-10
IN527MU2014 2014-02-14
IN2172MU2014 2014-07-04
PCT/IB2014/066720 WO2015087234A1 (en) 2013-12-10 2014-12-09 Bicyclic heteroaryl indole analogues useful as ror gamma modulators

Publications (1)

Publication Number Publication Date
MX2016007604A true MX2016007604A (es) 2017-02-28

Family

ID=52355020

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016007604A MX2016007604A (es) 2013-12-10 2014-12-09 Analogos de heteroaril indol biciclico utiles como moduladores de ror.

Country Status (18)

Country Link
US (1) US9682977B2 (es)
EP (1) EP3080090B1 (es)
JP (1) JP2016539989A (es)
CN (1) CN105980364A (es)
AP (1) AP2016009281A0 (es)
AU (1) AU2014363035A1 (es)
BR (1) BR112016013425A2 (es)
CA (1) CA2933003A1 (es)
CL (1) CL2016001441A1 (es)
EA (1) EA029489B1 (es)
IL (1) IL246123A0 (es)
MX (1) MX2016007604A (es)
PE (1) PE20160687A1 (es)
PH (1) PH12016501105A1 (es)
SG (1) SG11201604714SA (es)
TW (1) TW201605797A (es)
WO (1) WO2015087234A1 (es)
ZA (1) ZA201604454B (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201419015D0 (en) 2014-10-24 2014-12-10 Orca Pharmaceuticals Ltd Compounds
JP2018510135A (ja) 2015-02-11 2018-04-12 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． ＲＯＲγＴ阻害剤としての置換ピラゾール化合物及びその使用
WO2017051319A1 (en) * 2015-09-21 2017-03-30 Glenmark Pharmaceuticals S.A. Aryl and heteroaryl ether compounds as ror gamma modulators
CA3002850A1 (en) 2015-10-27 2017-05-04 Merck Sharp & Dohme Corp. Substituted indazole compounds as rorgammat inhibitors and uses thereof
JP2018531958A (ja) 2015-10-27 2018-11-01 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． ＲＯＲγＴ阻害薬としてのヘテロアリール置換安息香酸及びその使用
AU2016344111A1 (en) * 2015-10-27 2018-05-10 Merck Sharp & Dohme Corp. Substituted bicyclic pyrazole compounds as RORgammaT inhibitors and uses thereof
WO2017197055A1 (en) 2016-05-10 2017-11-16 C4 Therapeutics, Inc. Heterocyclic degronimers for target protein degradation
AR110481A1 (es) 2016-12-05 2019-04-03 Lead Pharma Holding Bv MODULADORES DE ROR g (RORg)
BR112019026945A2 (pt) * 2017-07-06 2020-06-30 Jiangsu Hengrui Medicine Co., Ltd. derivado de indol-formamida, método de preparação para ele e seu uso em medicina
US11466024B2 (en) 2017-08-01 2022-10-11 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Bicylic compound acting as an inhibitor
WO2019100106A1 (en) * 2017-11-24 2019-05-31 The University Of Sydney Antibacterial compounds and methods of use thereof

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200621237A (en) * 2004-11-01 2006-07-01 Wyeth Corp [(1-h-indazol-3-yl)methyl]phenols and (hydroxyphenyl)(1h-indazol-3-yl)methanones
WO2006075638A1 (ja) * 2005-01-14 2006-07-20 Dainippon Sumitomo Pharma Co., Ltd. 新規ヘテロアリール誘導体
WO2012024620A2 (en) * 2010-08-20 2012-02-23 Amira Pharmaceuticals, Inc. Autotaxin inhibitors and uses thereof
WO2012028100A1 (en) 2010-09-01 2012-03-08 Glaxo Group Limited Novel compounds
WO2012027965A1 (en) 2010-09-01 2012-03-08 Glaxo Group Limited Novel compounds
EP2638014B1 (en) * 2010-11-08 2017-01-04 Lycera Corporation N-sulfonylated tetrahydroquinolines and related bicyclic compounds for inhibition of ror-gamma activity and the treatment of diseases
WO2012100732A1 (en) 2011-01-24 2012-08-02 Glaxo Group Limited Retinoid-related orphan receptor gamma modulators, composition containing them and uses thereof
WO2012100734A1 (en) 2011-01-24 2012-08-02 Glaxo Group Limited Compounds useful as retinoid-related orphan receptor gamma modulators
EP2487159A1 (en) * 2011-02-11 2012-08-15 MSD Oss B.V. RorgammaT inhibitors
EP2511263A1 (en) 2011-04-14 2012-10-17 Phenex Pharmaceuticals AG Pyrrolo sulfonamide compounds for modulation of orphan nuclear receptor RAR-related orphan receptor-gamma (RORgamma, NR1F3) activity and for the treatment of chronic inflammatory and autoimmune diseases
WO2013171729A2 (en) 2013-01-08 2013-11-21 Glenmark Pharmaceuticals S.A. Aryl and heteroaryl amide compounds as rorgamat modulator

Also Published As

Publication number Publication date
TW201605797A (zh) 2016-02-16
IL246123A0 (en) 2016-08-02
AP2016009281A0 (en) 2016-06-30
AU2014363035A1 (en) 2016-06-30
EP3080090B1 (en) 2018-01-31
EA201691002A1 (ru) 2016-12-30
ZA201604454B (en) 2017-11-29
US9682977B2 (en) 2017-06-20
EP3080090A1 (en) 2016-10-19
CN105980364A (zh) 2016-09-28
BR112016013425A2 (pt) 2017-08-08
CA2933003A1 (en) 2015-06-18
JP2016539989A (ja) 2016-12-22
PE20160687A1 (es) 2016-08-11
WO2015087234A1 (en) 2015-06-18
US20160326163A1 (en) 2016-11-10
SG11201604714SA (en) 2016-07-28
CL2016001441A1 (es) 2017-03-03
PH12016501105A1 (en) 2016-07-11
EA029489B1 (ru) 2018-04-30

Similar Documents

Publication Publication Date Title
PH12016502045A1 (en) Aryl and heteroaryl ether compounds as ror gamma modulators
PH12016501105A1 (en) Bicyclic heteroaryl indole analogues useful as ror gamma modulators
PH12018500251A1 (en) Novel compounds as ror gamma modulators
WO2013171729A3 (en) Aryl and heteroaryl amide compounds as ror gamma t modulator
PH12016501791B1 (en) Muscarinic receptor agonists
SG10201810879VA (en) Pharmaceutical compounds
NZ766530A (en) Optionally fused heterocyclyl-substituted derivatives of pyrimidine useful for the treatment of inflammatory, metabolic, oncologic and autoimmune diseases
MX2017015741A (es) Moduladores de ror gamma (ror?).
MX2019014292A (es) Anillos 5-5 fusionados como inhibidores c5a.
MX2017015740A (es) Moduladores de ror gamma (ror?).
MX2017015739A (es) Moduladores de ror gamma (ror?).
PH12017501280B1 (en) Hydroxyalkyl-piperazine derivatives as cxcr3 receptor modulators
PH12018500411A1 (en) Novel carbocyclic compounds as ror gamma modulators
PH12017501876A1 (en) Pyridopyrimidones and their use as nmda receptor modulators
MX2016005348A (es) Compuestos novedosos.
PH12016502480A1 (en) Compounds, pharmaceutical composition and their use in treating neurodegenerative diseases
JOP20200104A1 (ar) مركبات مثبطة لـ btk
GB2519470A (en) Bicyclic aza compounds as muscarinic M1 receptor agonists